Condition: Hematological Malignancies · Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period.
This description comes directly from the study's public registry record.
Shuhua Yi · 15900265415 · yishuhua@ihcams.ac.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Anhui, China | Recruiting |
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
| Sun Yat-Sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| The Central Hospital of Wuhan | Wuhan, Hubei, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05728658